Clinical Trial Update: c-MET Inhibitor in Advanced Solid Tumors With c-MET Gene Aberration [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a c-MET inhibitor in advanced solid tumors with c-MET gene aberration is currently recruiting at Yonsei University.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• c-MET inhibitor

Snippet

Sponsor: Yonsei University | Conditions: Neoplasms | Phase 2 | Status: RECRUITING